# Pancreatic Adenocarcinoma Signature Stratification for Treatment

> **NCT04469556** · PHASE2 · COMPLETED · sponsor: **University Health Network, Toronto** · enrollment: 150 (actual)

## Conditions studied

- Pancreatic Cancer Metastatic
- Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Cancer

## Interventions

- **DRUG:** Folfirinox
- **DRUG:** Gemcitabine/nab-paclitaxel

## Key facts

- **NCT ID:** NCT04469556
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-14
- **Primary completion:** 2025-03-05
- **Final completion:** 2025-03-05
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2026-02-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04469556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04469556, "Pancreatic Adenocarcinoma Signature Stratification for Treatment". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04469556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*